148 related articles for article (PubMed ID: 34730559)
1. Changing Trends of Cirrhotic and Noncirrhotic Hepatocellular Carcinoma in the Era of Directly-Acting Antiviral Agents.
Mathur K; Mazhar A; Patel M; Dakhoul L; Burney H; Liu H; Nephew L; Chalasani N; deLemos A; Gawrieh S
Clin Transl Gastroenterol; 2021 Nov; 12(11):e00420. PubMed ID: 34730559
[TBL] [Abstract][Full Text] [Related]
2. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
[TBL] [Abstract][Full Text] [Related]
3. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients.
Cabibbo G; Celsa C; Calvaruso V; Petta S; Cacciola I; Cannavò MR; Madonia S; Rossi M; Magro B; Rini F; Distefano M; Larocca L; Prestileo T; Malizia G; Bertino G; Benanti F; Licata A; Scalisi I; Mazzola G; Di Rosolini MA; Alaimo G; Averna A; Cartabellotta F; Alessi N; Guastella S; Russello M; Scifo G; Squadrito G; Raimondo G; Trevisani F; Craxì A; Di Marco V; Cammà C;
J Hepatol; 2019 Aug; 71(2):265-273. PubMed ID: 30959157
[TBL] [Abstract][Full Text] [Related]
4. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals.
Prenner SB; VanWagner LB; Flamm SL; Salem R; Lewandowski RJ; Kulik L
J Hepatol; 2017 Jun; 66(6):1173-1181. PubMed ID: 28161470
[TBL] [Abstract][Full Text] [Related]
5. Impact of DAAs on liver transplantation: Major effects on the evolution of indications and results. An ELITA study based on the ELTR registry.
Belli LS; Perricone G; Adam R; Cortesi PA; Strazzabosco M; Facchetti R; Karam V; Salizzoni M; Andujar RL; Fondevila C; De Simone P; Morelli C; Fabregat-Prous J; Samuel D; Agarwaal K; Moreno Gonzales E; Charco R; Zieniewicz K; De Carlis L; Duvoux C;
J Hepatol; 2018 Oct; 69(4):810-817. PubMed ID: 29940268
[TBL] [Abstract][Full Text] [Related]
6. Hepatocellular carcinoma in the post-hepatitis C virus era: Should we change the paradigm?
Meringer H; Shibolet O; Deutsch L
World J Gastroenterol; 2019 Aug; 25(29):3929-3940. PubMed ID: 31413528
[TBL] [Abstract][Full Text] [Related]
7. Impact of All-Oral Direct-Acting Antivirals on Clinical and Economic Outcomes in Patients With Chronic Hepatitis C in the United States.
Park H; Wang W; Henry L; Nelson DR
Hepatology; 2019 Mar; 69(3):1032-1045. PubMed ID: 30289989
[TBL] [Abstract][Full Text] [Related]
8. TLL1 variants do not predict hepatocellular carcinoma development in HCV cirrhotic patients treated with direct-acting antivirals.
Degasperi E; Galmozzi E; Facchetti F; Farina E; D'Ambrosio R; Soffredini R; Iavarone M; Lampertico P
J Viral Hepat; 2019 Oct; 26(10):1233-1236. PubMed ID: 31177595
[TBL] [Abstract][Full Text] [Related]
9. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression.
Waziry R; Hajarizadeh B; Grebely J; Amin J; Law M; Danta M; George J; Dore GJ
J Hepatol; 2017 Dec; 67(6):1204-1212. PubMed ID: 28802876
[TBL] [Abstract][Full Text] [Related]
10. Decreasing frequency and improved outcomes of hepatitis C-related liver transplantation in the era of direct-acting antivirals - a retrospective cohort study.
Arora SS; Axley P; Ahmed Z; Satapathy SK; Wong R; Kuo YF; Singal AK
Transpl Int; 2019 Aug; 32(8):854-864. PubMed ID: 30866110
[TBL] [Abstract][Full Text] [Related]
11. Imaging features of microvascular invasion in hepatocellular carcinoma developed after direct-acting antiviral therapy in HCV-related cirrhosis.
Renzulli M; Buonfiglioli F; Conti F; Brocchi S; Serio I; Foschi FG; Caraceni P; Mazzella G; Verucchi G; Golfieri R; Andreone P; Brillanti S
Eur Radiol; 2018 Feb; 28(2):506-513. PubMed ID: 28894901
[TBL] [Abstract][Full Text] [Related]
12. Reduction in liver transplant wait-listing in the era of direct-acting antiviral therapy.
Flemming JA; Kim WR; Brosgart CL; Terrault NA
Hepatology; 2017 Mar; 65(3):804-812. PubMed ID: 28012259
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity.
Krassenburg LAP; Maan R; Ramji A; Manns MP; Cornberg M; Wedemeyer H; de Knegt RJ; Hansen BE; Janssen HLA; de Man RA; Feld JJ; van der Meer AJ
J Hepatol; 2021 May; 74(5):1053-1063. PubMed ID: 33242501
[TBL] [Abstract][Full Text] [Related]
14. De Novo Hepatocellular Carcinoma Among Liver Transplant Registrants in the Direct Acting Antiviral Era.
Kwong AJ; Kim WR; Flemming JA
Hepatology; 2018 Oct; 68(4):1288-1297. PubMed ID: 29672886
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis C virus related cirrhosis decreased as indication to liver transplantation since the introduction of direct-acting antivirals: A single-center study.
Ferrarese A; Germani G; Gambato M; Russo FP; Senzolo M; Zanetto A; Shalaby S; Cillo U; Zanus G; Angeli P; Burra P
World J Gastroenterol; 2018 Oct; 24(38):4403-4411. PubMed ID: 30344424
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and risk factors for hepatocellular carcinoma in individuals with haemophilia in the era of direct-acting antiviral agents: A national inpatient sample study.
Yang X; Jeong K; Yabes JG; Ragni MV
Haemophilia; 2022 Sep; 28(5):769-775. PubMed ID: 35727998
[TBL] [Abstract][Full Text] [Related]
17. Hepatic Fat-Genetic Risk Score Predicts Hepatocellular Carcinoma in Patients With Cirrhotic HCV Treated With DAAs.
Degasperi E; Galmozzi E; Pelusi S; D'Ambrosio R; Soffredini R; Borghi M; Perbellini R; Facchetti F; Iavarone M; Sangiovanni A; Valenti L; Lampertico P
Hepatology; 2020 Dec; 72(6):1912-1923. PubMed ID: 32762045
[TBL] [Abstract][Full Text] [Related]
18. Hepatocellular carcinoma in cirrhotic versus noncirrhotic livers: results from a large cohort in the Netherlands.
van Meer S; van Erpecum KJ; Sprengers D; Coenraad MJ; Klümpen HJ; Jansen PL; IJzermans JN; Verheij J; van Nieuwkerk CM; Siersema PD; de Man RA
Eur J Gastroenterol Hepatol; 2016 Mar; 28(3):352-9. PubMed ID: 26629867
[TBL] [Abstract][Full Text] [Related]
19. The impact of treatment of hepatitis C with DAAs on the occurrence of HCC.
Roche B; Coilly A; Duclos-Vallee JC; Samuel D
Liver Int; 2018 Feb; 38 Suppl 1():139-145. PubMed ID: 29427487
[TBL] [Abstract][Full Text] [Related]
20. Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection.
Degasperi E; D'Ambrosio R; Iavarone M; Sangiovanni A; Aghemo A; Soffredini R; Borghi M; Lunghi G; Colombo M; Lampertico P
Clin Gastroenterol Hepatol; 2019 May; 17(6):1183-1191.e7. PubMed ID: 30613002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
